Drugs / 68Ga-NOTA-AE105
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02437539 | May → Aug 2015 | breast cancer, prostate cancer, urinary bladder cancer | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03307460 | Nov 2017 → Oct 2019 | prostate cancer | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT03278275 | Nov 2017 → Jul 2021 | neuroendocrine neoplasm | Rigshospitalet, Denmark | Completed | No outcome recorded |
| Phase 2 | NCT02945826 | Jan 2017 → Dec 2020 | glioblastoma | Rigshospitalet, Denmark | Unknown | No outcome recorded |
| Phase 2 | NCT02964988 | Jan 2017 → Oct 2019 | metastatic carcinoma in the bone, metastatic prostate carcinoma | Rigshospitalet, Denmark | Terminated | No outcome recorded |
| Phase 2 | NCT02805608 | Sep 2016 → Jan 2019 | urinary bladder neoplasm | Rigshospitalet, Denmark | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 68Ga-NOTA-AE105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02437539 ↗ |
| Modality | Peptide | “a linear, high-affinity uPAR peptide antagonist, AE105” PMID 22213823 ↗ Jan 2012 |
| Route | Intravenous | “One injection intravenously of 68Ga-NOTA-AE105” NCT02805608 ↗ |